Chronic Immune Thrombocytopenia clinical trials at UC Davis
1 research study open to eligible people
Study to Evaluate the Effectiveness and Safety of Experimental PANZYGA in Children With Chronic Immune Thrombocytopenia (ITP)
open to eligible people ages 1-18
This is a prospective, open-label, single-arm, multicenter, Phase 4 study evaluating the efficacy and safety of PANZYGA in pediatric patients with chronic ITP.
Sacramento, California and other locations